ARPA-H commits $62.7M to develop FDA-authorized AI for heart failure treatment

ARPA-H announced a $62.7 million investment to develop AI-driven clinical decision support tools for heart failure, aiming for FDA authorization. The initiative signals a major federal push to integrate AI into regulated medical treatment pathways, though the specific technology and timeline remain unspecified. This could accelerate AI adoption in cardiology and set a precedent for AI in other therapeutic areas.